The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ELCC 2016 | Targetable immune checkpoint molecules in lung cancer

Name: Targetable immune checkpoint molecules in lung cancer
Uploaded: 2016-04-15T00:00:00.000Z
Duration: 1 min
Description: At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, discusses multiple immune checkpoint molecules, including PD-L2, gamma interferon, IDO, TIM3 LAG-3 B7H3, that may have clinical relevance for the treatment of patients with lung cancer.

Joseph Paul Eder • 15 Apr 2016

ELCC 2016

Lung Cancer

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, discusses multiple immune checkpoint molecules, including PD-L2, gamma interferon, IDO, TIM3 LAG-3 B7H3, that may have clinical relevance for the treatment of patients with lung cancer.

1:57

Targeting PD-1 and PD-L1 for lung cancer therapy

Joseph Paul Eder • 15 Apr 2016

ELCC 2016 | Targetable immune checkpoint molecules in lung cancer

More from Joseph Paul Eder

Related Videos

Cookie settings